Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E-Based ADCs

• Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs
• SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan
• Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020)

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the Company was awarded Best Poster at Hanson Wade’s 2021 World ADC Conference. Separately, Synaffix was also awarded ‘Runner-Up’ for the Best ADC Platform Technology.

New data presented in the winning poster, titled: “GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability Data” demonstrated complete tumor regression and high tolerability of SYNtecan E™ based ADCs, and underscores the ability of Synaffix’s technologies to enable best-in-class, next generation ADCs.

This marks the fifth year that Synaffix’ groundbreaking ADC platform technology has been acknowledged at the World ADC Awards ceremony as industry-leading, by a judging panel of world-renowned ADC experts.  The 2021 finalists were shortlisted through a voting pool of over 2,500 individuals, with a panel of distinguished, independent industry experts from across the ADC field assessing each finalist to decide the winners.